The Alzheimer drug latrepirdine (Dimebon) did not meet wither of its primary research targets in a late-stage clinical study, faring no better than a placebo at treating the disease, according to Pfizer Inc., the drug's manufacturer.  The Alzheimer's Association is dissappointed to learn of the negative Phase III clinical trials results, but we remain optimistic about the furture prospects for better Alzheimer treatments and prevention strategies.

Read the Associated Press arcticle